Cambridge Nutrition. - Director/PDMR Shareholding

Cambridge Nutritional Sciences

19/11/2025 07:00

RNS Number : 0749I

Cambridge Nutritional Sciences PLC

19 November 2025

 

Cambridge Nutritional Sciences plc

(the 'Company' or 'CNS')

 

Director/PDMR Shareholding

 

CNS (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has received notification that Carolyn Rand, Non-Executive Chair of the Company, has purchased 150,000 ordinary shares of 4 pence each in the Company ("Ordinary Shares"), at an average price of 2.32 pence each. Jeremy Millard, Non-Executive Director of the Company, has also purchased 168,776 Ordinary Shares in the Company, at a price of 2.37 pence each.

 

A summary of Carolyn Rand and Jeremy Millard's resultant holdings is below:

 

Director
Board Position
Number of Ordinary Shares acquired
Total beneficial holding of Ordinary Shares following this acquisition
Number of Ordinary Shares
Approximate % of Company's issued share capital
Carolyn Rand
Non-Executive Chair
150,000
347,500
0.14%
Jeremy Millard
Non-Executive Director
168,776
1,193,776
0.50%

 

 

Contacts: 

 

Cambridge Nutritional Sciences plc
www.cnsplc.com
Carolyn Rand, Non-Executive Chair
James Cooper, Interim Chief Executive
Cavendish Capital Markets Limited
Tel: 020 7220 0500
Geoff Nash / Edward Whiley (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)


 

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

 

 

Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Carolyn Rand
2
Reason for the notification
a)
Position/status
Non-Executive Chair
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Cambridge Nutritional Sciences plc
b)
LEI
2138007U9P4BTZTYIR92
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 4 pence each
ISIN: GB00B1VCP282
b)
Nature of the transaction
Ordinary Shares purchased
c)
Price(s) and volume(s)
Price(s)
Volume(s)
2.30 pence
100,000
2.365 pence
50,000
d)
Aggregated information
-Aggregated volume
- Price
Aggregated volume - 150,000
Price - 2.3216
e)
Date of the transaction
18.11.2025
f)
Place of the transaction
London Stock Exchange

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Jeremy Millard
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Cambridge Nutritional Sciences plc
b)
LEI
2138007U9P4BTZTYIR92
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 4 pence each
ISIN: GB00B1VCP282
b)
Nature of the transaction
Ordinary Shares purchased
c)
Price(s) and volume(s)
Price(s)
Volume(s)
2.37 pence
168,776
d)
Aggregated information
-Aggregated volume
- Price
As above.
e)
Date of the transaction
18.11.2025
f)
Place of the transaction
London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHDGBDBIXBDGUI